Highest-materiality recent filing
Keros reports Q1 net loss $23.7M; Takeda plans Phase 3 for elritercept in myelofibrosis
Net loss $23.7M in Q1 2026 vs net income $148.5M in Q1 2025 due to prior-year Takeda license revenue.
Entered agreement with Massachusetts General Hospital for Phase 2 ALS trial within HEALEY ALS MyMatch program.
Keros Therapeutics reports Q4 net loss $23.5M, full-year net income $87.0M
Q4 2025 net loss $23.5M vs. $46.0M loss in Q4 2024; FY 2025 net income $87.0M vs. $187.4M loss in FY 2024.
Keros Therapeutics corporate presentation highlights Phase 2 data and cash runway into 2028
Phase 2 KER-050 in lower-risk MDS: 45% RBC transfusion independence at 24 weeks (ASH Dec 2025).
Keros net loss narrows to $7.3M in Q3; cash runway into H1 2028
Net loss of $7.3M in Q3 2025 versus $53.0M in Q3 2024, driven by Takeda license revenue.
Keros repurchases $181M of stock from ADAR1 & Pontifax at $17.75; plans $194M tender offer
Agreed to repurchase all shares held by ADAR1 (13.3%) and Pontifax (11.8%) at $17.75/share for ~$181M total.
Keros receives FDA Orphan Drug designation for KER-065 in Duchenne muscular dystrophy
FDA granted Orphan Drug designation for KER-065, a TGF-ß family protein-targeting therapy for DMD.
Keros Q2 net loss narrows to $30.7M; Board plans $375M capital return to stockholders
Net loss of $30.7M in Q2 2025 improved from $45.3M in Q2 2024, driven by Takeda license revenue.
Keros discontinues cibotercept development, prioritizes KER-065; CEO becomes President, COO departs
Discontinuing all internal development of cibotercept (KER-012) after PAH trial termination.
Keros doses first patient in Phase 3 RENEW trial of elritercept; $10M milestone from Takeda
First patient dosed in Phase 3 RENEW trial of elritercept for adults with transfusion-dependent anemia with very low, low, or intermediate risk MDS.
Keros Therapeutics CMO Yung Chyung resigns effective Aug 1, 2025
Chief Medical Officer Yung H. Chyung, M.D. resigned effective August 1, 2025.
Keros Therapeutics concludes strategic review, plans $375M capital return
Board unanimously approved $375M excess capital return to stockholders; structure and terms to be announced.
Keros ends PAH program, cuts 45% of staff, expects $17M annual savings
TROPOS trial discontinued after pericardial effusion safety events; all cibotercept PAH development halted.
Keros Q1 net income $148.5M on Takeda license; cash $720.5M; KER-065 Phase 2 plan Q1 2026
Net income of $148.5M vs net loss of $43.1M YoY; revenue driven by Takeda license agreement.
Keros Therapeutics adopts poison pill and launches strategic review including potential sale
Board formed Strategic Committee to evaluate strategic alternatives including sale or business combination.
Keros announces positive Phase 1 results for KER-065; plans Phase 2 in DMD in Q1 2026
KER-065 generally well-tolerated; no serious adverse events or dose-limiting toxicities reported.
Keros Therapeutics Q4 2024 net loss $46.0M; receives $200M Takeda upfront for elritercept
Net loss of $46.0M in Q4 2024 vs $40.2M in Q4 2023; full-year net loss $187.4M.
Keros-Takeda license for elritercept effective; $200M upfront payment triggered
Global license agreement with Takeda (TSE:4502/NYSE:TAK) for elritercept became effective Jan 16, 2025.
Keros halts entire Phase 2 PAH trial (all doses, placebo) on pericardial effusion safety
Voluntary halt of all dosing in TROPOS trial, including 1.5 mg/kg and placebo arms, due to new pericardial effusion adverse events.
Keros halts two high-dose arms of Phase 2 PAH trial after pericardial effusion
Voluntarily halted dosing in 3.0 mg/kg and 4.5 mg/kg cibotercept arms in ongoing TROPOS trial.
Keros reports elritercept Phase 2 data: 134.1 wk median TI in MDS; spleen reductions in MF
55.2% (48/87) of mITT patients achieved overall erythroid response; median TI duration 134.1 weeks in lower-risk MDS.
Keros licenses elritercept to Takeda for $200M upfront; milestones up to $1.1B
Upfront payment of $200M; eligible for up to $370M in development/commercial milestones and $740M in sales milestones.
Keros Q3 net loss $53M; cash $530.7M; Phase 2 PAH trial fully enrolled
Net loss of $53.0M in Q3 2024 vs $39.4M in Q3 2023; R&D expenses rose to $49.2M.
Keros completes Phase 2 PAH trial TROPOS enrollment with 113 patients; topline Q2 2025
Completed enrollment of TROPOS Phase 2 trial of cibotercept (KER-012) for pulmonary arterial hypertension.
Keros closes screening for Phase 2 TROPOS trial in PAH; expects topline data in Q2 2025
Phase 2 TROPOS trial of cibotercept (KER-012) for PAH has closed screening.
Keros reports durable transfusion independence in Phase 2 MDS trial; plans registrational Phase 3
Overall erythroid response 55.6% (45/81) in modified ITT patients; 41.3% (26/63) of TI-evaluable achieved ≥8-week transfusion independence.
Keros Therapeutics files prospectus supplement for up to $350M at-the-market stock offering
Filed prospectus supplement on June 17, 2024 to sell up to $350 million of common stock via ATM program.
Keros receives positive FDA feedback on KER-050 MDS program; Phase 3 design aligned
FDA feedback resulted in general alignment on design and endpoints for proposed pivotal Phase 3 trial of KER-050 (elritercept) in MDS.
Carl L. Gordon currently serves as the Chair of the Board and, effective June 30, 2024, will resign from such position and serve as a member of the Board.
the Board appointed Jean-Jacques Bienaimé as Lead Independent Director, effective July 1, 2024.
The Board appointed Christopher Rovaldi to the additional position as the Company’s President, effective July 1, 2024.
On February 29, 2024, Simon Cooper, M.B.B.S., resigned from his position as Chief Medical Officer of Keros Therapeutics, Inc. (the “Company”), effective March 12, 2024, to pursue other opportunities.
Max materiality 0.85 · Median 0.62 · Most common event other_material